Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and β-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years fo...cusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.
TY - JOUR
AU - Ismaili, L
AU - Refouvelet, B
AU - Benchekroun, M
AU - Brogi, S
AU - Brindisi, M
AU - Gemma, S
AU - Campiani, G
AU - Filipić, Slavica
AU - Agbaba, Danica
AU - Esteban, Gerard
AU - Unzeta, Mercedes
AU - Nikolić, Katarina
AU - Butini, Stefania
AU - Marco-Contelles, Jose
PY - 2017
UR - http://farfar.pharmacy.bg.ac.rs/handle/123456789/2916
AB - Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and β-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years focusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.
PB - Elsevier Ltd
T2 - Progress in Neurobiology
T1 - Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease
VL - 151
SP - 4
EP - 34
DO - 10.1016/j.pneurobio.2015.12.003
ER -
@article{
author = "Ismaili, L and Refouvelet, B and Benchekroun, M and Brogi, S and Brindisi, M and Gemma, S and Campiani, G and Filipić, Slavica and Agbaba, Danica and Esteban, Gerard and Unzeta, Mercedes and Nikolić, Katarina and Butini, Stefania and Marco-Contelles, Jose",
year = "2017",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/2916",
abstract = "Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and β-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years focusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.",
publisher = "Elsevier Ltd",
journal = "Progress in Neurobiology",
title = "Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease",
volume = "151",
pages = "4-34",
doi = "10.1016/j.pneurobio.2015.12.003"
}
Ismaili, L., Refouvelet, B., Benchekroun, M., Brogi, S., Brindisi, M., Gemma, S., Campiani, G., Filipić, S., Agbaba, D., Esteban, G., Unzeta, M., Nikolić, K., Butini, S.,& Marco-Contelles, J. (2017). Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease.
Progress in Neurobiology
Elsevier Ltd., 151, 4-34.
https://doi.org/10.1016/j.pneurobio.2015.12.003
Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipić S, Agbaba D, Esteban G, Unzeta M, Nikolić K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Progress in Neurobiology. 2017;151:4-34
Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipić Slavica, Agbaba Danica, Esteban Gerard, Unzeta Mercedes, Nikolić Katarina, Butini Stefania, Marco-Contelles Jose, "Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease" Progress in Neurobiology, 151 (2017):4-34,
https://doi.org/10.1016/j.pneurobio.2015.12.003 .
